Related Experiment Video

Updated: Jul 11, 2026

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells

Yongjin Park1, Soo-Kyung Shon, Aeyung Kim

  • 1Department of Biological Sciences and the Research Center for Women's Diseases, Sookmyung Women's University, Chungpa-Dong, Yongsan-Gu, Seoul 140-742, Republic of Korea.

Biochemical and Biophysical Research Communications
|September 25, 2007
PubMed

Insights

NDRG2 overexpression in breast cancer inhibits Akt and STAT3 phosphorylation by up-regulating SOCS1 via p38 MAPK. This implicates NDRG2 as a tumor suppressor in cancer signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • NDRG2 (NMYC downstream regulated gene 2) role in tumorigenesis is known, but its function in intracellular signaling pathways is unclear.
  • Understanding NDRG2's role is crucial for developing targeted breast cancer therapies.

Purpose of the Study:

  • To investigate the role of NDRG2 in regulating intracellular signal transduction pathways in breast cancer cells.
  • To elucidate the molecular mechanisms by which NDRG2 influences key signaling molecules like Akt, p38 MAPK, JNK, and JAK/STAT.

Main Methods:

  • Overexpression of NDRG2 in malignant breast cancer cells.
  • Analysis of protein phosphorylation (Akt, p38 MAPK, SAPK/JNK, JAK2, STAT3).
  • Assessment of SOCS1 (Suppressor of Cytokine Signaling 1) mRNA and protein levels.
  • Investigating the role of p38 MAPK in NDRG2-mediated signaling.

Main Results:

  • NDRG2 overexpression inhibited Akt phosphorylation and induced p38 MAPK and SAPK/JNK phosphorylation.
  • NDRG2 suppressed JAK2 and STAT3 activation.
  • NDRG2 significantly upregulated SOCS1 expression.
  • Inhibition of p38 MAPK reversed NDRG2-induced SOCS1 expression and restored STAT3 phosphorylation.

Conclusions:

  • NDRG2 inhibits STAT3 activation in breast cancer cells through SOCS1 induction in a p38 MAPK-dependent manner.
  • NDRG2 acts as a growth inhibitory gene by modulating signal transduction pathways in breast tumor cells.
  • These findings highlight NDRG2 as a potential therapeutic target in breast cancer treatment.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...